Resomelagon clinical trials
Includes 6 studies of Resomelagon acetate.
How each study uses resomelagon is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the resomelagon studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Resomelagon
- 1
Studies by the year they started
7 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
SynAct Pharma Aps (6) · Federal University of Minas Gerais (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test resomelagon.
- Jun 2027Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)Phase 2 · Federal University of Minas Gerais
- Aug 2027A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory VirusesPhase 2 · SynAct Pharma Aps
Studies
Open first, then newest update. How each study uses resomelagon is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)RecruitingPhase 2Federal University of Minas GeraisNCT06917001Written as Resomelagon
- A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory VirusesRecruitingPhase 2SynAct Pharma ApsNCT07633288Written as AP1189, 100 mg
- A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe ProteinuriaRecruitingPhase 2SynAct Pharma ApsNCT04456816Written as 100 mg AP1189
- A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid ArthritisRecruitingPhase 2SynAct Pharma ApsNCT06671054Written as AP1189, 40 mg
- A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to MethotrexateCompletedPhase 2SynAct Pharma ApsNCT05604885Written as AP1189, 60 mg
- A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint DiseaseCompletedPhase 2SynAct Pharma ApsNCT04004429Written as 50 mg AP1189
- A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD TreatmentCompletedPhase 2SynAct Pharma ApsNCT05516979Written as 100 mg AP1189
Codes
What other systems call resomelagon · ClinicalTrials.gg INT017384
- UNII (FDA) NF7M2ZJA9YRESOMELAGONOne source FDA
- NCI Thesaurus C190472ResomelagonOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NF7M2ZJA9Y | RESOMELAGON | One source FDA |
| NCI Thesaurus | C190472 | Resomelagon | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.